When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...

Healthcare stocks have gotten crushed in 2024, and next year doesn’t look much better. But there are still opportunities for ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

The company is well-positioned to continue gaining momentum against Novo in weight loss while simultaneously leading the ...

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

Leveraging insights from OpenAI’s ChatGPT, Finbold has curated a $1,000 stock portfolio designed to capture growth ...

The Japanese company urged Biden to reflect on the steps it has taken to address national-security concerns. One crew member was in intensive care after engine problems and smoke in the cabin and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Both Eli Lilly and Novo Nordisk have invested in GLP-1 injectables ... designed to help relieve manufacturing bottlenecks for injectable GLP-1 drugs Mounjaro and Zepbound. The company doubled its ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...